Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchEnveda Launches ENV-294, the First AI-Discovered Drug Candidate for Atopic Dermatitis into Clinical Trials
Nov 13, 2024
BoulderOtherBiotechnology
Product Description
Enveda has announced that the FDA has cleared its first investigational new drug candidate, ENV-294, for clinical trials targeting atopic dermatitis. This marks a significant milestone for the biotechnology company, as ENV-294 is the first drug discovered from nature through AI and modern medicinal chemistry.
Company Information
Company
Enveda Therapeutics, Inc.
Location
5777 CROWNTREE LANE APT 202
Boulder, Colorado, United States
About
Enveda Biosciences is a biotechnology company building the first high-resolution chemical map of the natural world to tackle the toughest problems in drug discovery. Enveda’s platform is the world’s most advanced drug discovery search engine for dark chemical space, building on years of cutting-edge advancements at the intersection of metabolomics and machine learning. Complementing its breakthrough technology, Enveda’s team includes seasoned drug hunters with decades of experience in the pharmaceutical industry working alongside world-leading data scientists. For more information on Enveda, visit envedabio.com.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Enveda Therapeutics, Inc. ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BoulderOtherBiotechnology